Free Trial
OTCMKTS:DSNKY

Daiichi Sankyo Q4 2026 Earnings Results & Report

Daiichi Sankyo logo
$17.68 -0.54 (-2.96%)
As of 11/10/2026 03:58 PM Eastern

Daiichi Sankyo missed analyst earnings expectations but beat on revenue in its Q4 2026 results, released May 11, 2026. The company reported EPS of $0.15 versus the $0.3317 consensus estimate, while revenue of $3.76 billion topped the $3.74 billion estimate by $16.76 million.

Earnings Announcement Details

Quarter
Q4 2026
Report Date
Time
Before Market Opens

Daiichi Sankyo EPS Results

Actual EPS
$0.15
Consensus EPS
$0.3317
Beat/Miss
Missed by -$0.1817
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Daiichi Sankyo Revenue Results

Actual Revenue
$3.76 billion
Expected Revenue
$3.74 billion
Beat/Miss
Beat by +$16.76 million
YoY Revenue Growth
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Q4 2026 Earnings FAQ

Daiichi Sankyo (OTCMKTS:DSNKY) reported earnings of $0.15 per share for Q4 2026, missing the consensus estimate of $0.3317. The report was announced on Monday, May 11, 2026.

Daiichi Sankyo reported revenue of $3.76 billion for Q4 2026, against a consensus estimate of $3.74 billion.

Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for Daiichi Sankyo on the company's earnings history page.

Daiichi Sankyo Earnings Headlines

Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Earnings Beat
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions.

Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib). Daiichi Sankyo also invests in research and development, including antibody-drug conjugates and other targeted therapies.

Headquartered in Tokyo, Daiichi Sankyo serves patients and healthcare providers in Japan and international markets, including the United States and Europe. It works with partners in some markets to develop and commercialize medicines.

View Daiichi Sankyo Profile